borderline non-significantp = 0.052
The double application group showed significant improvements from baseline at 30 days across all WOMAC outcomes and NPRS, as seen by the mean differences from baseline at the patient-level endpoint (last available visit): WOMAC Total −13.72 points (95% CI −18.25 to −9.19, r = 0.775, n = 57); Pain −2.53 (95% CI −3.60 to −1.46, r = 0.718); Stiffness −0.96 (95% CI −1.47 to −0.45, d = −0.50, paired t -test); Physical Function −10.23 (95% CI −13.47 to −6.99, r = 0.811); and NPRS −1.13 (95% CI −2.19 to −0.07, n = 38, Wilcoxon p = 0.052, borderline non-significant).